Drugs / Tavapadon
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT06895356 | Mar → Jun 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05581823 | Oct 2022 → Jan 2023 | Parkinson disease | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05404542 | May 2022 → Aug 2023 | impaired renal function disease | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05404529 | Apr 2022 → Jan 2023 | liver disease, severe congenital | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04241393 | Feb → Nov 2020 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04295642 | Jan 2020 → Jul 2021 | Parkinson disease | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03121664 | Apr → Sep 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02373072 | Mar 2015 → Feb 2016 | Parkinson disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02262767 | Nov → Dec 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02224664 | Oct 2014 → Mar 2016 | Parkinson disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02066909 | Feb 2014 → Apr 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01981694 | Nov 2013 → Feb 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03185481 | Jul → Oct 2017 | Parkinson disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT02847650 | Oct 2016 → Jan 2018 | Parkinson disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT02687542 | Mar 2016 → Nov 2017 | Parkinson disease | Pfizer | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04760769 | Feb 2021 → Dec 2025 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04542499 | Sep 2020 → Jan 2024 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04223193 | Jan 2020 → Oct 2024 | Parkinson disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT04201093 | Dec 2019 → Jun 2024 | Parkinson disease | AbbVie | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07158827 Background | — | Parkinson disease | AbbVie | Available | No outcome recorded |
Press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-26 | AbbVie | AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease abbvie.com ↗ |
| 2024-12-09 | AbbVie | AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease abbvie.com ↗ |
| 2024-09-26 | AbbVie | AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease abbvie.com ↗ |
| 2024-04-18 | AbbVie | Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease abbvie.com ↗ |
| 2023-11-29 | AbbVie | Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease abbvie.com ↗ |
| 2021-04-13 | AbbVie | Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon abbvie.com ↗ |
| 2020-10-30 | AbbVie | Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease abbvie.com ↗ |
| 2020-01-14 | AbbVie | Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease abbvie.com ↗ |
| 2019-09-23 | AbbVie | Cerevel Therapeutics Announces Positive Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease abbvie.com ↗ |
| 2019-09-19 | AbbVie | Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease abbvie.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tavapadon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06895356 ↗ |
| Known as | CVL-751 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04295642 ↗ |
| Known as | PF-06649751 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02687542 ↗ |
| Action | Activate | “PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson's disease treatment.” PMID 30361858 ↗ Oct 20182“Dopamine D5 receptor partial agonist” CHEMBL3697617 ↗ “Dopamine D1 receptor partial agonist” CHEMBL3697617 ↗ |
| Modality | Small molecule | — CHEMBL3697617 ↗ |
| Route | Oral | “given orally” NCT01981694 ↗ |
| Target | DRD1 | “Dopamine D1 receptor partial agonist” CHEMBL3697617 ↗ |
| Target | DRD5 | “Dopamine D5 receptor partial agonist” CHEMBL3697617 ↗ |